GH Research GHRS
NASDAQ GHRS
$28.23 +0.31 (+1.11%)
As of: Sep 4, 2026 · 3:59 PM EDT

GH Research (GHRS) Share-based Compensation (2021 - 2026)

GH Research (GHRS) posted quarterly Share-based Compensation of $2.7 million for Q4 2025, up 249.93% year-over-year from $759000.0 in Q4 2024, and up 15.48% quarter-over-quarter from $2.3 million in Q3 2025.

Analysis

GH Research (GHRS) Share-based Compensation (2021 - 2026) Analysis & Trends

GH Research's Share-based Compensation history runs 5 years deep, the most recent figure standing at $2.7 million for Q4 2025.

  • In Q4 2025, Share-based Compensation rose 249.93% year-over-year to $2.7 million; the TTM figure through Dec 2025 stood at $8.5 million (up 586.97% YoY), while the FY2025 annual figure was $13.1 million, up 167.72% from the prior year.
  • Share-based Compensation for Q4 2025 stood at $2.7 million, up from $2.3 million in the prior quarter.
  • The five-year high for Share-based Compensation was $2.7 million in Q4 2025, with the low at -$100000.0 in Q2 2024.
  • The 5-year median for Share-based Compensation is $444000.0 (2022), against an average of $768444.4.
  • The sharpest annual moves came in 2024 and 2025: Share-based Compensation sank 125.0% in 2024, then jumped 2000.0% in 2025.
  • GH Research's Share-based Compensation stood at $269000.0 in 2021, then jumped by 81.41% to $488000.0 in 2022, then surged by 33.4% to $651000.0 in 2023, then grew by 16.59% to $759000.0 in 2024, then soared by 249.93% to $2.7 million in 2025.
  • Business Quant data shows GHRS's Share-based Compensation at $2.7 million in Q4 2025, $2.3 million in Q3 2025, and $1.9 million in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 108.10 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 243.00 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 120.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 277.20 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 137.41 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 86.63 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 41.25 Mn
10 GH Research 1.72 Bn 1.36 Bn - 2.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.20 Mn
Mar 31, 2026 1.83 Mn
Dec 31, 2025 2.66 Mn
Sep 30, 2025 2.30 Mn
Jun 30, 2025 1.90 Mn
Mar 31, 2025 1.64 Mn
Dec 31, 2024 759,000.00
Sep 30, 2024 300,000.00
Jun 30, 2024 -100,000.00
Mar 31, 2024 277,000.00
Dec 31, 2023 642,000.00
Sep 30, 2023 600,000.00
Jun 30, 2023 400,000.00
Mar 31, 2023 551,000.00
Dec 31, 2022 488,000.00
Sep 30, 2022 400,000.00
Jun 30, 2022 300,000.00
Mar 31, 2022 327,000.00
Dec 31, 2021 235,000.00
Sep 30, 2021 119,000.00